Page 288 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.7. Tumor characteristics—stage (continued)
Author Database Stage groups 1980-84 1985- 1990-94 1995-99 2000-04 2005- Statistical Notes
Year 89 10 analysis
PMID
63
Mullins SEER- OR for diagnosis Reference OR=0.76 P<0.01 Analyses were
2010 Medicare with distant vs. in year (0.69, limited to
20163844 situ, local or (1998) 0.83) OR adjusted patients with
regional disease, (2002) for marital available stage
using 1998 as the status, information.
reference year. urban/rural Additional
living area, information on
state-buy-in, interactions of
PSA test prior patient age with
to diagnosis, time trends are
census tract presented in
median Table 6 of the
household paper.
income, SEER
registry.
65
Cooperberg CaPSURE T stage NR
2002 T1 21.6% 45.4%
12131295 T2 68.6% 50.2%
T3 9.1% 3.7%
T4 0.7% 0.5%
(1989-97) (1997-
2001)
4
Cooperberg CaPSURE T stage
2003 T1 16.9% 30.6% 49.4% P<0.001
14610406 T2a 48.2% 36.0% 27.2% (Mantel-
T2b 23.0% 25.8% 20.0% Haenszel test
T3-4 11.8% 7.5% 3.5% for trend)
(1989-92) (1996-99) (1999-
2002)
67
Cooperberg CaPSURE T2a 74.6% 60.2% 36.2% NR Low-risk prostate
2004 T1c 15.2% 35.9% 61.7% cancer patients
15169800 T1b 5.4% 2.3% 0.5% only (n=1990)
T1a 4.9% 1.6% 1.6%
(1989-92) (1996-98) (1999-
2001)

C-62